Predicting the unpredictable: Transmission of drug-resistant HIV

Nature Medicine

Volumn 7, Issue 9, 2001, Pages 1016-1020

  Blower, S M ^a   Aschenbach, A N ^a   Gershengorn, H B ^b   Kahn, J O ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

ARTICLE; DISEASE TRANSMISSION; DRUG SENSITIVITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION CONTROL; MATHEMATICAL MODEL; PREVALENCE; PRIORITY JOURNAL; PUBLIC HEALTH; STRAIN DIFFERENCE;

ANTI-HIV AGENTS; DRUG RESISTANCE, MICROBIAL; HIV INFECTIONS; HIV-1; HUMANS; MODELS, THEORETICAL; SAN FRANCISCO;

EID: 0034785773     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/nm0901-1016     Document Type: Article

References (39)

1. Global trends in resistance to antituberculosis drugs
2. Control strategies for tuberculosis epidemics: New models for old problems
3. Understanding, predicting and controlling the emergence of drug-resistant tuberculosis: A theoretical framework
4. Antibiotic resistance - To treat…(or not to treat)?
5. Predicting and preventing the emergence of antiviral drug resistance in HSV-2
6. Health care policy: U.S. Priorities - HIV prevention
7. AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: The Swiss HIV cohort study
8. Improved survival among HIV-infected individuals following initiation of antiretroviral therapy
9. Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration
10. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection
11. Sexual transmission of an HIV-1 variant resistant to multiple reverse-transcriptase and protease inhibitors
12. Reduced antiretroviral drug susceptibility among patients with primary HIV infection
13. Prevalence of HIV-1 resistant to antiretroviral drugs in 81 individuals newly infected by sexual contact or injecting drug use
14. Transmission of antiretroviral-drug-resistant HIV-1 variants
15. A tale of two futures: HIV and antiretroviral therapy in San Francisco
16. Increases in unsafe sex and rectal gonorrhea among men who have sex with men - San Francisco, California, 1994-1997
17. Resurgent bacterial sexually transmitted disease among men who have sex with men - King County, Washington, 1997-1999
18. Outbreak of syphilis among men who have sex with men - Southern California, 2000
19. Patterns of plasma human immunodeficiency virus type 1 RNA response to antiretroviral therapy
20. Reasons for discontinuation of first highly active antiretroviral therapy in a cohort of protease inhibitor-naive HIV-infected patients
21. Strategies for long-term success in the treatment of HIV infection
22. Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy
23. A randomized trial of three maintenance regimens given after three months of induction therapy with zidovudine, lamivudine, and indinavir in previously untreated HIV-1-infected patients
24. Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens
25. Comparison of the effectiveness of non-nucleoside reverse transcriptase inhibitor-containing and protease inhibitor-containing regimens using observational databases
26. Predictors of virological success and ensuing failure in HIV-positive patients starting highly active antiretroviral therapy in Europe: Results from the Euro SIDA study
27. Development of drug resistance in patients receiving combinations of zidovudine, didanosine and nevirapine
28. Sensitivity and uncertainty analysis of complex models of disease transmission: An HIV model, as an example
29. The intrinsic transmission dynamics of tuberculosis epidemics
30. Viral load and heterosexual transmission of HIV-1
31. Is transmitted drug resistance in HIV on the rise?
32. Impaired replication of protease inhibitor-resistant HIV-1 in human thymus
33. 1998 Revision to the British HIV Association guidelines for antiretroviral treament of HIV seropositive individuals
34. Public health consequences of screening patients for adherence to highly active antiretroviral therapy
35. Live attenuated HIV vaccines: Predicting the trade-off between efficacy and safety
36. Calculating the consequences: HAART and risky sex
37. An investigation of uncertainty and sensitivity analysis techniques for computer models
38. Statistical analyses of scatterplots to identify important factors in large-scale simulations, 1: Review and comparison of techniques